Prescription for Rheumatoid Arthritis
Start with oral methotrexate 15 mg weekly (titrated to this dose within 4-6 weeks), combined with folic acid supplementation and a short course of low-dose glucocorticoids (≤3 months). This represents the gold standard initial therapy for rheumatoid arthritis based on the most recent international guidelines 1, 2.
Initial Prescription Details
For a newly diagnosed RA patient with moderate-to-high disease activity:
- Methotrexate: Start 7.5-10 mg orally once weekly, escalate to at least 15 mg weekly within 4-6 weeks (optimal dose 25-30 mg weekly if tolerated) 1, 3
- Folic acid: 5 mg weekly (taken on a different day than methotrexate) or 1 mg daily 4, 1
- Prednisone: 5-10 mg daily, taper over 4-12 weeks and discontinue 1, 5
For patients with low disease activity:
- Consider hydroxychloroquine 200-400 mg daily as first-line, or sulfasalazine 2-3 g daily (better tolerated, less immunosuppressive) 1, 6
Optimization Strategies
If gastrointestinal intolerance to oral methotrexate develops:
- Switch to subcutaneous methotrexate 15-25 mg weekly 1, 7
- Or split the oral dose over 24 hours 1
- Increase folic acid supplementation 1
If inadequate response after 3 months on optimized methotrexate:
- Add a biologic DMARD (TNF inhibitor preferred initially: adalimumab, etanercept, certolizumab, golimumab, or infliximab) 1, 2
- Alternative: Add triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) in patients without poor prognostic factors 8, 7
Treatment Algorithm
Phase 1 (Months 0-3):
- Initiate methotrexate monotherapy with short-term glucocorticoids
- Assess response at 3 months using validated disease activity measures
- Target: Low disease activity or remission
Phase 2 (If inadequate response at 3-6 months):
- With poor prognostic factors (positive RF/anti-CCP, erosions, high disease activity): Add biologic DMARD 2, 9
- Without poor prognostic factors: Add another csDMARD or triple therapy 3, 5
Phase 3 (If first biologic fails):
- Switch to another biologic from same or different class, OR
- Switch to JAK inhibitor (tofacitinib, baricitinib, upadacitinib) after careful cardiovascular and malignancy risk assessment 2, 9
Critical Prescribing Considerations
Methotrexate dosing is frequently suboptimal in practice - the evidence strongly supports rapid escalation to 15-25 mg weekly rather than remaining at low doses 4, 3. Maximum efficacy requires 4-6 months at optimal dosing before declaring treatment failure 3.
Subcutaneous methotrexate has superior bioavailability at higher doses (>15 mg) and should be considered for patients not reaching target on oral therapy, even before adding biologics 4, 1, 7.
Glucocorticoid toxicity outweighs benefits beyond 3 months - the strong recommendation against longer-term use reflects significant risks of cardiovascular disease, osteoporosis, and infections 1, 6. Use the lowest effective dose for the shortest duration.
Poor prognostic factors mandate earlier biologic therapy: presence of anti-CCP antibodies, rheumatoid factor, erosions on imaging, or persistently high disease activity despite optimal methotrexate 3, 2.
Common Pitfalls to Avoid
- Underdosing methotrexate: Many clinicians stop at 10-15 mg weekly; optimal dosing is 25-30 mg weekly 4, 3
- Premature treatment escalation: Allow 3-6 months at optimal methotrexate dose before declaring failure 3, 5
- Prolonged glucocorticoid use: Taper and discontinue within 3 months 1, 2
- Forgetting folic acid: Essential for reducing methotrexate toxicity 4, 1
- Not using treat-to-target approach: Systematic monitoring and treatment adjustment to achieve remission or low disease activity is strongly recommended 1
The 2025 EULAR update emphasizes cardiovascular and malignancy risk stratification when considering JAK inhibitors, particularly in patients >65 years, with cardiovascular risk factors, or smoking history 2, 9.